Can Two Successes Outweigh Eleven Failures? FDA Evidence Threshold Is Put Back on the Table

Drug approval has never been merely the sum of scientific data. It is also a test of public trust. When a drug is described as having only a small number of successes in clinical trials while accumulating multiple missed endpoints, the question no longer stops at whether there is statistical significance. It becomes whether the regulatory system can clearly explain to physicians and patients which results are sufficient to demonstrate efficacy, and which silences or failures cannot be lightly passed over.

On June 26, The People's Pharmacy published a commentary titled “FDA Drug Approval Standards: Can 2 Wins Erase 11 Losses?”, using the question of whether “two wins can erase eleven losses” to reexamine how the U.S. Food and Drug Administration (FDA) views positive and negative trials in drug review. Because the publicly available summary is currently quite brief, it is not yet possible to confirm the drug, indication, trial design, or definition of failure referred to in the article. Therefore, this event is better viewed as a warning sign about regulatory evidence standards rather than as a conclusion about the efficacy of a specific product.

The core concept in U.S. drug approval is substantial evidence formed by “adequate and well-controlled studies.” Traditionally, two independent, rigorously designed, and consistent positive clinical trials have often been regarded as an important foundation for supporting efficacy. But modern drug development increasingly involves more complex evidence packages, including one large positive trial accompanied by supportive data, accelerated approval based on surrogate endpoints, or acceptance of smaller-scale and more uncertain evidence in rare diseases.

The difficulty is that if two positive results are placed among a large number of negative or missed-endpoint trials, interpretation becomes challenging. Negative trials may stem from incorrect dosing, imprecise selection of patient populations, or poor endpoint design, or they may indicate that the drug’s true efficacy is limited. If regulators choose to accept a small number of successful trials, they usually must explain whether those successes are biologically plausible, whether they are reproduced in key populations, and whether safety risks have been adequately understood.

This type of controversy also reflects the dual pressure the FDA has faced in recent years. On one hand, patients with serious diseases, rare diseases, and few treatment options need faster access to new drugs that may help. On the other hand, excessive reliance on limited or selectively interpreted evidence may allow products with uncertain efficacy to enter the market, shifting the burden of subsequent validation onto the healthcare system and patients.

**Background Context**

Recent U.S. regulatory discussions have repeatedly centered on the speed of clinical development, flexibility in early trials, and evidence quality. If these reforms can bring truly effective therapies into clinical use more quickly, they do have public health value. But speed itself is not the answer. When review standards are loosened or interpreted more flexibly, transparent disclosure of complete trial results and clear labeling of uncertainty become more important than ever.

At present, there are no additional sources on the same event available to cross-check details, which limits judgment on the individual case. What is certain is that the question of “two wins and eleven losses” sounds jarring because it touches the most fundamental promise of drug regulation: approval should not simply mean finding enough bright spots to clear the bar, but should be a judgment on the full body of evidence that can withstand scrutiny.